GOSS vs SERA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
GOSS exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating the weakest possible fundamental health. The company suffers from negative equity (Price/Book of -0.71) and an unsustainable operating margin of -333.65%. Despite positive revenue growth, the stock is in a catastrophic technical death spiral, losing over 85% of its value in the last six months. The massive discrepancy between the current price ($0.37) and the analyst target ($3.69) suggests a significant lag in analyst updates or extreme speculative optimism not supported by the deterministic data.
SERA presents a contradictory profile with a stable Piotroski F-Score of 6/9 but catastrophic operational metrics. While the balance sheet remains lean with very low debt (D/E 0.03) and adequate liquidity, the company is experiencing a severe revenue collapse (-58.3% YoY) and negative gross margins (-102.47%), indicating that the cost of producing its services exceeds the revenue generated. The extreme Price-to-Sales ratio (1111.49) and aggressive insider selling suggest a lack of confidence in the current business model, rendering the single analyst's 'strong buy' rating highly speculative.
Compare Another Pair
Related Comparisons
GOSS vs SERA: Head-to-Head Comparison
This page compares Gossamer Bio, Inc. (GOSS) and Sera Prognostics, Inc. (SERA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.